Logo image of SRRK

SCHOLAR ROCK HOLDING CORP (SRRK) Stock Fundamental Analysis

NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD

32.45  -0.87 (-2.61%)

After market: 32.45 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SRRK. SRRK was compared to 559 industry peers in the Biotechnology industry. SRRK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SRRK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SRRK had negative earnings in the past year.
In the past year SRRK has reported a negative cash flow from operations.
SRRK had negative earnings in each of the past 5 years.
SRRK had a negative operating cash flow in each of the past 5 years.
SRRK Yearly Net Income VS EBIT VS OCF VS FCFSRRK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -64.82%, SRRK is not doing good in the industry: 61.72% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -84.58%, SRRK is in line with its industry, outperforming 50.09% of the companies in the same industry.
Industry RankSector Rank
ROA -64.82%
ROE -84.58%
ROIC N/A
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
SRRK Yearly ROA, ROE, ROICSRRK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SRRK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRRK Yearly Profit, Operating, Gross MarginsSRRK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SRRK has more shares outstanding
The number of shares outstanding for SRRK has been increased compared to 5 years ago.
The debt/assets ratio for SRRK has been reduced compared to a year ago.
SRRK Yearly Shares OutstandingSRRK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRRK Yearly Total Debt VS Total AssetsSRRK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 15.34 indicates that SRRK is not in any danger for bankruptcy at the moment.
SRRK's Altman-Z score of 15.34 is amongst the best of the industry. SRRK outperforms 90.88% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that SRRK is not too dependend on debt financing.
The Debt to Equity ratio of SRRK (0.16) is worse than 68.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 15.34
ROIC/WACCN/A
WACCN/A
SRRK Yearly LT Debt VS Equity VS FCFSRRK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 10.25 indicates that SRRK has no problem at all paying its short term obligations.
SRRK has a Current ratio of 10.25. This is in the better half of the industry: SRRK outperforms 79.25% of its industry peers.
A Quick Ratio of 10.25 indicates that SRRK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.25, SRRK is in the better half of the industry, outperforming 79.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.25
Quick Ratio 10.25
SRRK Yearly Current Assets VS Current LiabilitesSRRK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SRRK have decreased strongly by -21.53% in the last year.
EPS 1Y (TTM)-21.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SRRK will show a very strong growth in Earnings Per Share. The EPS will grow by 23.41% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.25%
EPS Next 2Y16.79%
EPS Next 3Y28.56%
EPS Next 5Y23.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRRK Yearly Revenue VS EstimatesSRRK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
SRRK Yearly EPS VS EstimatesSRRK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SRRK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRRK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRRK Price Earnings VS Forward Price EarningsSRRK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRRK Per share dataSRRK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as SRRK's earnings are expected to grow with 28.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.79%
EPS Next 3Y28.56%

More info and screens

0

5. Dividend

5.1 Amount

SRRK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCHOLAR ROCK HOLDING CORP

NASDAQ:SRRK (6/13/2025, 8:00:01 PM)

After market: 32.45 0 (0%)

32.45

-0.87 (-2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners118.28%
Inst Owner Change12.42%
Ins Owners3.75%
Ins Owner Change5.8%
Market Cap3.08B
Analysts85.33
Price Target51.44 (58.52%)
Short Float %16.85%
Short Ratio11.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.69%
Min EPS beat(2)0.64%
Max EPS beat(2)0.74%
EPS beat(4)3
Avg EPS beat(4)-0.75%
Min EPS beat(4)-7.78%
Max EPS beat(4)3.39%
EPS beat(8)5
Avg EPS beat(8)0.01%
EPS beat(12)8
Avg EPS beat(12)4.94%
EPS beat(16)10
Avg EPS beat(16)7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)-5.51%
EPS NY rev (1m)-3.18%
EPS NY rev (3m)-8.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)27.26%
Revenue NY rev (3m)27.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.86
P/tB 9.86
EV/EBITDA N/A
EPS(TTM)-2.54
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.42
OCFYN/A
SpS0
BVpS3.29
TBVpS3.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.82%
ROE -84.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.25
Quick Ratio 10.25
Altman-Z 15.34
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.34%
Cap/Depr(5y)103.43%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.56%
EPS Next Y-0.25%
EPS Next 2Y16.79%
EPS Next 3Y28.56%
EPS Next 5Y23.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.24%
EBIT Next 3Y34.81%
EBIT Next 5YN/A
FCF growth 1Y-72.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.59%
OCF growth 3YN/A
OCF growth 5YN/A